1-3 of 3
Kimberly Hayes
Close
Sort by
Journal Articles

Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha

Clinical Trials & Observations
Peter McLaughlin, Elihu Estey, Armand Glassman, Jorge Romaguera, Felipe Samaniego, Ana Ayala, Kimberly Hayes, Anne Marie Maddox, H. Alejandro Preti, Fredrick B. Hagemeister
Journal: Blood
Blood (2005) 105 (12): 4573–4575.
https://doi.org/10.1182/blood-2004-08-3035
Published: 2005
Journal Articles

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

Clinical Trials & Observations
Alfonso Quintas-Cardama, Hagop Kantarjian, Moshe Talpaz, Susan O'Brien, Guillermo Garcia-Manero, Srdan Verstovsek, Mary Beth Rios, Kimberly Hayes, Armand Glassman, B. Nebiyou Bekele, Xian Zhou, Jorge Cortes
Journal: Blood
Blood (2005) 105 (6): 2281–2286.
https://doi.org/10.1182/blood-2004-06-2208
Published: 2005
Journal Articles

Myelodysplasia and Acute Myeloid Leukemia Following Therapy for Indolent Lymphoma with Fludarabine, Mitoxantrone, Dexamethasone (FND) Plus Rituximab and Interferon Alfa.

Peter McLaughlin, MD, Elihu Estey, MD, Armand Glassman, MD, Jorge Romaguera, MD, Felipe Samaniego, MD, PhD, Ana Ayala, RN, Kimberly Hayes, Anne Marie Maddox, MD, PhD, H. Alejandro Preti, MD, Fredrick B. Hagemeister, MD
Journal: Blood
Blood (2004) 104 (11): 1394.
https://doi.org/10.1182/blood.V104.11.1394.1394
Published: 2004